1887

Abstract

Of the cephalosporins, cefpodoxime has the most published clinical data for the treatment of urinary tract infections. In 2014, the Clinical and Laboratory Standards Institute (CLSI) guidelines recommended that cefazolin should be used as the surrogate marker for cefpodoxime among urinary tract isolates, replacing cephalothin. This study attempted to determine how well cefazolin serves as the surrogate marker. Additionally, it investigated how cefuroxime compared with cefazolin as a surrogate marker. The MicroScan Walkaway Plus system was used to determine susceptibility for cefazolin and cefuroxime on consecutive urine cultures with a colony count of ≥ 50 000 organisms. Only and isolates were included, following CLSI guidelines. Simultaneously, an Etest for cefpodoxime was conducted. The cefpodoxime interpretation was compared with that of the other two agents, and the categorical agreement was calculated, defined as the percentage of identical susceptibility interpretations. Cefazolin (92 %) had a significantly higher categorical agreement than cefuroxime (85 %) among 284 isolates ( = 0.011). The major error rate was 4.4 % for cefazolin and 1.1 % for cefuroxime. The very major error rate was 64 % for cefazolin and 18 % for cefuroxime among the 11 cefpodoxime-resistant isolates. Cefazolin was a better predictor of cefpodoxime susceptibility than the previously recommended agent, cephalothin. However, cefuroxime had better major and very major error rates than cefazolin.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000142
2015-10-01
2019-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jmm/64/10/1170.html?itemId=/content/journal/jmm/10.1099/jmm.0.000142&mimeType=html&fmt=ahah

References

  1. Bookstaver D. A., Bland C. M., Woodberry M. W., Mansell K. B.. ( 2014;). Correlation of cefpodoxime susceptibility with cephalothin and cefuroxime for urinary tract isolates. J Med Microbiol 63: 218–221 [CrossRef] [PubMed].
    [Google Scholar]
  2. Brown P. D., Freeman A., Foxman B.. ( 2002;). Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis 34: 1061–1066 [CrossRef] [PubMed].
    [Google Scholar]
  3. CLSI ( 2013;). Performance Standards for Antimicrobial Susceptibility Testing 23rd Informational Supplement. CLSI document M100-S23 Wayne, PA: Clinical and Laboratory Standards Institute;.
    [Google Scholar]
  4. CLSI ( 2015;). Performance Standards for Antimicrobial Susceptibility Testing 25th Informational Supplement. CLSI document M100-S25 Wayne, PA: Clinical and Laboratory Standards Institute;.
    [Google Scholar]
  5. Gottesman B. S., Carmeli Y., Shitrit P., Chowers M.. ( 2009;). Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis 49: 869–875 [CrossRef] [PubMed].
    [Google Scholar]
  6. Gupta K., Hooton T. M., Naber K. G., Wullt B., Colgan R., Miller L. G., Moran G. J., Nicolle L. E., Raz R., other authors. ( 2011;). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52: e103–e120 [CrossRef] [PubMed].
    [Google Scholar]
  7. Hooton T. M., Roberts P. L., Stapleton A. E.. ( 2012;). Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA 307: 583–589 [CrossRef] [PubMed].
    [Google Scholar]
  8. Johnson L., Sabel A., Burman W. J., Everhart R. M., Rome M., MacKenzie T. D., Rozwadowski J., Mehler P. S., Price C. S.. ( 2008;). Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 121: 876–884 [CrossRef] [PubMed].
    [Google Scholar]
  9. Kavatha D., Giamarellou H., Alexiou Z., Vlachogiannis N., Pentea S., Gozadinos T., Poulakou G., Hatzipapas A., Koratzanis G.. ( 2003;). Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. Antimicrob Agents Chemother 47: 897–900 [CrossRef] [PubMed].
    [Google Scholar]
  10. Olson R. P., Harrell L. J., Kaye K. S.. ( 2009;). Antibiotic resistance in urinary isolates of Escherichia coli from college women with urinary tract infections. Antimicrob Agents Chemother 53: 1285–1286 [CrossRef] [PubMed].
    [Google Scholar]
  11. US FDA ( 2007;). Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems Silver Spring, MD: US Department of Health and Human Services Food and Drug Administration, Center for Devices and Radiological Health; http://www.fda.gov/RegulatoryInformation/Guidances/ucm080564.htm.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000142
Loading
/content/journal/jmm/10.1099/jmm.0.000142
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error